GlassScriptPhysician profile
Sylvia Rozek
NPI 1104071588
$2,110.05
in general payments reported to CMS, 2019-2025
18 companies · $296 in 2025
The $296 reported for 2025 was more than what 75% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.83 · 2021: $188 · 2022: $37.68 · 2023: $16.33 · 2024: $1,525 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,129 · Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,128.70 |
| Food and Beverage | $708.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,527.92 | 2024-2025 | |
| Hydrocision, INC. | $159.37 | 2025 | Tenjet |
| Kerecis Limited | $72.06 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Bioventus LLC | $65.43 | 2021-2024 | Exogen Ultrasound Bone Healing System |
| Novo Nordisk INC | $52.40 | 2020-2021 | |
| Lilly USA, LLC | $35.36 | 2021 | |
| Avanos Medical | $22.53 | 2024 | On-Q* Pump and Accessories |
| Amgen INC. | $21.97 | 2020 | |
| Ferring Pharmaceuticals INC. | $19.90 | 2022 | |
| Depuy Synthes Sales INC. | $19.18 | 2024 | Monovisc |
| Takeda Pharmaceuticals U.S.A., INC. | $19.05 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2021 | |
| Organogenesis INC. | $16.33 | 2023 | Puraply |
| Merck Sharp & Dohme LLC | $13.49 | 2021 | |
| Bausch Health US, LLC | $13.31 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.78 | 2021 | |
| Abbvie INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Rozek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.